Spots Global Cancer Trial Database for Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Official Title: A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Study ID: NCT05494697
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma
Detailed Description: This is a Phase 2, randomized, open-label controlled study to evaluate the efficacy and safety of Ampligen treatment compared to a control group / no treatment following FOLFIRINOX treatment in subjects with locally advanced pancreatic adenocarcinoma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nebraska Medical Center, Omaha, Nebraska, United States
Gabrail Cancer Center Research, Canton, Ohio, United States
Virginia Mason Medical Center, Seattle, Washington, United States
Contact Details
Name: David R Strayer, MD
Affiliation: AIM ImmunoTech Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
